Search
Benralizumab
go.drugbank.com/drugs/DB12023ApprovedInvestigational[A31294] It inhibits the binding of IL-5 as well as the hetero-oligomerization of the alpha and beta subunits of the IL-5R, thus blocking signal transduction. … Benralizumab is a humanized recombinant monoclonal antibody of the isotype IgG1k immunoglobulin that specifically binds to the alpha chain of the interleukin 5 receptor (IL-5R) expressed on eosinophils
Categories: Interleukin-5 Receptor alpha-directed Cytolytic Antibody, Interleukin 5 Receptor alpha-directed Antibody InteractionsProducts: Fasenra 30 mg solution for injection in pre-filled syringe, FASENRA 30 MG/ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖRCefotaxime
go.drugbank.com/drugs/DB00493ApprovedInvestigationalLike other third-generation cephalosporins, it has broad spectrum activity against Gram positive and Gram negative bacteria.
Mixtures: ALVIM 1000, SEFOTAK 1 G IM ENJEKSİYONLUK TOZ İÇEREN FLAKON, 1 ADETSynonyms: (6R,7R,Z)-3-(acetoxymethyl)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid, (6R,7R)-3-Acetoxymethyl-7-{2-(2-amino-thiazol-4-yl)-2-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acidLomitapide
go.drugbank.com/drugs/DB08827Approved[A7367] Lomitapide was first approved by the FDA in December 2012 and the EMA in July 2013 as an adjunct to a low-fat diet and other lipid-lowering treatments.[A275444, A275446] … [A275444, A7367] It was developed to address the significant unmet medical need in patients with homozygous familial hypercholesterolemia (HoFH)—an ultra-rare and life-threatening genetic disorder characterized
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 SubstratesProducts: JUXTAPID CAPSULAS POR 10 MG, JUXTAPID® CÁPSULAS POR 5 MGSalicylic acid
go.drugbank.com/drugs/DB00936ApprovedInvestigationalVet approvedIt has bacteriostatic, fungicidal, and keratolytic actions. Its salts, the salicylates, are used as analgesics.
Mixtures: Actikerall 5 mg/g + 100 mg/g Lösung zur Anwendung auf der Haut, ÜRESAL FORTE %10 + %10 MERHEM (50 G)Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesInterferon alfa-n1
go.drugbank.com/drugs/DB00011ApprovedWithdrawnInterferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produc...
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme InhibitorsProducts: Wellferon Inj 10 000 000unit/ml, WELLFERON INYECTABLE 10 MU/ML.Carvedilol
go.drugbank.com/drugs/DB01136ApprovedInvestigational[A182306] Carvedilol was granted FDA approval on 14 September 1995.[L7889] … [L7889,L7892] The dual action of carvedilol is advantageous in combination therapies as moderate doses of 2 drugs have a decreased incidence of adverse effects compared to high dose monotherapy in the
Mixtures: Co-Dilatrend 25 mg/12,5 mg - Filmtabletten, CARIVALAN 25/5Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesCilazapril
go.drugbank.com/drugs/DB01340ApprovedInvestigationalIt is branded as Inhibace in Canada and other countries, Vascace and Dynorm in a number of European countries, among many other names. None of these varieties are available in the United States.
Mixtures: ACEPRIX PLUS 5 MG/12.5 MG FILM TABLET, 30 ADET, Inhibace plus 5 mg/12,5 mg - FilmtablettenProducts: ACEPRIX 5 MG FILM TABLET, 30 ADET, Inhibace 5 mg - FilmtablettenDoripenem
go.drugbank.com/drugs/DB06211ApprovedWithdrawnDoripenem injection was approved by the FDA in 2007 to treat complicated urinary tract and intra-abdominal infections. … In a clinical trial of doripenem treatment in ventilator associated pneumonia (vs. imipenem and cilastatin), it was found that doripenem carried an increased risk of death and lower clinical cure rates
Products: REDIDOR 500 MG /VIAL, DOREXTRA® DORIPENEM 500 MGIfosfamide
go.drugbank.com/drugs/DB01181ApprovedInvestigationalIt is active as an alkylating agent and an immunosuppressive agent.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2A6 SubstratesProducts: HOLOXAN 500 MG IV İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN TOZ, 1 ADET, โฮล๊อกซาน 500 มก.Mineral oil
go.drugbank.com/drugs/DB11057ApprovedInvestigationalVet approvedIt is also used as a mild laxative for human or veterinary uses. … Unrefined or mildly treated mineral oils are classified as Group 3 carcinogens by the World Health Organizations, as chronic exposure to these aromatics including alkylated polycyclic aromatic compounds
Mixtures: retaine MGD, AGAROL M (EMULSION)Products: LIQUID PARAFFIN EMULSION 2.5 ml/5 ml, LAXAROL ORAL EMULSION 50% v/v